Avient Corporation AVNT logged earnings from continuing operations of 52 cents per share in the fourth quarter of 2024, up from earnings of 30 cents it had reported a year ago.
Barring one-time items, adjusted earnings for the reported quarter came in at 49 cents per share. It beat the Zacks Consensus Estimate of 48 cents.
Find the latest earnings estimates and surprises on Zacks Earnings Calendar.
Avient raked in revenues of $746.5 million, up around 4% year over year. It, however, missed the Zacks Consensus Estimate of $751.2 million. Organic sales were up 5% year over year aided by growth in all geographic regions.
Avient Corporation price-consensus-eps-surprise-chart | Avient Corporation Quote
Sales from the Color, Additives and Inks unit were $467.7 million in the reported quarter, up roughly 2% year over year. It was below the consensus estimate of $479 million.
Specialty Engineered Materials recorded sales of $279.7 million, up around 8% year over year. It was above the consensus estimate of $277 million.
Earnings (as reported) for full-year 2024 was $1.84 per share, up from 83 cents per share a year ago. Net sales rose around 3% year over year to $3,240.4 million.
Avient ended 2024 with cash and cash equivalents of roughly $544.5 million, flat year over year. Long-term debt was around $2,059.3 million, down around 0.5% from the prior year.
Net cash provided by operating activities was $256.8 million for full-year 2024, up around 27% year over year.
The company expects full-year 2025 adjusted earnings in the range of $2.70-$2.94 per share. the mid-point represents an 11% growth excluding the unfavorable currency impact. AVNT sees adjusted EBITDA in the band of $540-$570 million for the full year.
Avient projects first-quarter adjusted earnings to be 76 cents per share. This represents a 6% growth, excluding the currency impact.
Avient’s shares have gained 8.8% in the past year compared with the Zacks Chemicals Diversified industry’s 3.2% decline.
Image Source: Zacks Investment Research
AVNT currently carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the Basic Materials space are Ingevity Corporation NGVT, ICL Group Ltd ICL and Nutrien Ltd. NTR. While NGVT carries a Zacks Rank #1 (Strong Buy), ICL and NTR have a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Ingevity is scheduled to release fourth-quarter results on Feb.18. The Zacks Consensus Estimate for NGVT’s fourth-quarter earnings is pegged at 12 cents. NGVT surpassed the Zacks Consensus Estimate in three of the trailing four quarters while missing once. It has a trailing four-quarter earnings surprise of 95.4%, on average.
ICL Group is slated to release fourth-quarter results on Feb.26. The consensus estimate for ICL’s fourth-quarter earnings is pegged at 6 cents. It surpassed the Zacks Consensus Estimate for earnings in each of the last four quarters at an average of 18.1%.
Nutrien is scheduled to release fourth-quarter results on Feb.19. The Zacks Consensus Estimate for NTR’s fourth-quarter earnings is pegged at 33 cents.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ICL Group Ltd. (ICL) : Free Stock Analysis Report
Ingevity Corporation (NGVT) : Free Stock Analysis Report
Nutrien Ltd. (NTR) : Free Stock Analysis Report
Avient Corporation (AVNT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.